Bifogade filer
Ziccum appoints new Scientific Director
DSC 8606
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ziccum AB has appointed a Scientific Director, as part of a major reorganisation aiming to facilitate and accelerate its new strategic focus on key projects and vaccine platforms. Ziccum Senior Formulation Specialist Fabrice Rose will assume the new role. The reorganization was implemented on August 1, 2022.
Ziccum AB has appointed Fabrice Rose, until recently its Senior Formulation Specialist, as its new Scientific Director. Fabrice Rose is the author or co-author of 16 peer-reviewed publications on vaccine formulation. His 20 years’ plus experience in formulation and drug delivery includes ten year’s lab work specializing in the design and characterization of nanoparticulate vaccine formulations and investigating the physical stability of protein antigens.
Strong team focus
The reorganisation, the result of extensive consultation and collaboration, is an integral part of Ziccum’s new sharpened strategic focus, initiated with the arrival of new CEO Ann Gidner in May 2022. It has created new roles and clarified existing ones as the company deepens its project work and targets three key vaccine platforms.
CEO Ann Gidner: “I warmly welcome Fabrice to his new role. This reorganization will help us harness the great competence and commitment we have in-house in the best possible way. With a clear company focus and well-defined roles we can move ahead more efficiently and achieve great results together.”